Clinicopathological evaluation of cyclooxygenase-2 expression in meningioma

Immunohistochemical analysis of 76 cases of low and high-grade meningioma

Yasutaka Kato, Hiroshi Nishihara, Hiromi Mohri, Hiromi Kanno, Hiroyuki Kobayashi, Taichi Kimura, Mishie Tanino, Shunsuke Terasaka, Shinya Tanaka

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Tumorigenic activity of cyclooxygenase-2 (COX-2), a rate-limiting enzyme in the production of prostaglandins (PGs), has been proved for some types of cancer, including brain tumors. We evaluated expression of COX-2 in meningioma, one of the most common intracranial tumors in adults which accounts for 24-30% of intracranial tumors. We performed immunostaining for COX-2 in 76 cases of meningioma consisting of 44 cases of low-grade (WHO Grade I) and 32 cases of high-grade (29 cases of Grade II and 3 cases of Grade III) meningioma, and evaluated COX-2 expression levels on the basis of staining intensity and proportion in tumor cells. The expression level of COX-2 in meningioma cells was significantly correlated with WHO grade ( P = 0.0153). In addition, COX-2 expression was significantly correlated with MIB-1 labeling index for all 76 cases of meningioma (P = 0.0075), suggesting tumor promotion by COX-2 in meningioma progression. Our results may indicate the therapeutic value of non-steroidal anti-inflammatory drugs against meningioma, especially for patients with elevated proliferation, to regulate the tumorigenic activity of COX-2 in meningioma cells.

Original languageEnglish
Pages (from-to)23-30
Number of pages8
JournalBrain tumor pathology
Volume31
Issue number1
DOIs
Publication statusPublished - 2014 Jan 1
Externally publishedYes

Fingerprint

Meningioma
Cyclooxygenase 2
Brain Neoplasms
Neoplasms
Prostaglandins
Anti-Inflammatory Agents
Staining and Labeling
Enzymes
Pharmaceutical Preparations

Keywords

  • Clinicopathological analysis
  • Cyclooxygenase-2
  • Immunohistochemistry
  • Meningioma

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Clinicopathological evaluation of cyclooxygenase-2 expression in meningioma : Immunohistochemical analysis of 76 cases of low and high-grade meningioma. / Kato, Yasutaka; Nishihara, Hiroshi; Mohri, Hiromi; Kanno, Hiromi; Kobayashi, Hiroyuki; Kimura, Taichi; Tanino, Mishie; Terasaka, Shunsuke; Tanaka, Shinya.

In: Brain tumor pathology, Vol. 31, No. 1, 01.01.2014, p. 23-30.

Research output: Contribution to journalArticle

Kato, Yasutaka ; Nishihara, Hiroshi ; Mohri, Hiromi ; Kanno, Hiromi ; Kobayashi, Hiroyuki ; Kimura, Taichi ; Tanino, Mishie ; Terasaka, Shunsuke ; Tanaka, Shinya. / Clinicopathological evaluation of cyclooxygenase-2 expression in meningioma : Immunohistochemical analysis of 76 cases of low and high-grade meningioma. In: Brain tumor pathology. 2014 ; Vol. 31, No. 1. pp. 23-30.
@article{d9c8a6aa36054348a67e04b3efb4f71b,
title = "Clinicopathological evaluation of cyclooxygenase-2 expression in meningioma: Immunohistochemical analysis of 76 cases of low and high-grade meningioma",
abstract = "Tumorigenic activity of cyclooxygenase-2 (COX-2), a rate-limiting enzyme in the production of prostaglandins (PGs), has been proved for some types of cancer, including brain tumors. We evaluated expression of COX-2 in meningioma, one of the most common intracranial tumors in adults which accounts for 24-30{\%} of intracranial tumors. We performed immunostaining for COX-2 in 76 cases of meningioma consisting of 44 cases of low-grade (WHO Grade I) and 32 cases of high-grade (29 cases of Grade II and 3 cases of Grade III) meningioma, and evaluated COX-2 expression levels on the basis of staining intensity and proportion in tumor cells. The expression level of COX-2 in meningioma cells was significantly correlated with WHO grade ( P = 0.0153). In addition, COX-2 expression was significantly correlated with MIB-1 labeling index for all 76 cases of meningioma (P = 0.0075), suggesting tumor promotion by COX-2 in meningioma progression. Our results may indicate the therapeutic value of non-steroidal anti-inflammatory drugs against meningioma, especially for patients with elevated proliferation, to regulate the tumorigenic activity of COX-2 in meningioma cells.",
keywords = "Clinicopathological analysis, Cyclooxygenase-2, Immunohistochemistry, Meningioma",
author = "Yasutaka Kato and Hiroshi Nishihara and Hiromi Mohri and Hiromi Kanno and Hiroyuki Kobayashi and Taichi Kimura and Mishie Tanino and Shunsuke Terasaka and Shinya Tanaka",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s10014-012-0127-8",
language = "English",
volume = "31",
pages = "23--30",
journal = "Brain Tumor Pathology",
issn = "1433-7398",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Clinicopathological evaluation of cyclooxygenase-2 expression in meningioma

T2 - Immunohistochemical analysis of 76 cases of low and high-grade meningioma

AU - Kato, Yasutaka

AU - Nishihara, Hiroshi

AU - Mohri, Hiromi

AU - Kanno, Hiromi

AU - Kobayashi, Hiroyuki

AU - Kimura, Taichi

AU - Tanino, Mishie

AU - Terasaka, Shunsuke

AU - Tanaka, Shinya

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Tumorigenic activity of cyclooxygenase-2 (COX-2), a rate-limiting enzyme in the production of prostaglandins (PGs), has been proved for some types of cancer, including brain tumors. We evaluated expression of COX-2 in meningioma, one of the most common intracranial tumors in adults which accounts for 24-30% of intracranial tumors. We performed immunostaining for COX-2 in 76 cases of meningioma consisting of 44 cases of low-grade (WHO Grade I) and 32 cases of high-grade (29 cases of Grade II and 3 cases of Grade III) meningioma, and evaluated COX-2 expression levels on the basis of staining intensity and proportion in tumor cells. The expression level of COX-2 in meningioma cells was significantly correlated with WHO grade ( P = 0.0153). In addition, COX-2 expression was significantly correlated with MIB-1 labeling index for all 76 cases of meningioma (P = 0.0075), suggesting tumor promotion by COX-2 in meningioma progression. Our results may indicate the therapeutic value of non-steroidal anti-inflammatory drugs against meningioma, especially for patients with elevated proliferation, to regulate the tumorigenic activity of COX-2 in meningioma cells.

AB - Tumorigenic activity of cyclooxygenase-2 (COX-2), a rate-limiting enzyme in the production of prostaglandins (PGs), has been proved for some types of cancer, including brain tumors. We evaluated expression of COX-2 in meningioma, one of the most common intracranial tumors in adults which accounts for 24-30% of intracranial tumors. We performed immunostaining for COX-2 in 76 cases of meningioma consisting of 44 cases of low-grade (WHO Grade I) and 32 cases of high-grade (29 cases of Grade II and 3 cases of Grade III) meningioma, and evaluated COX-2 expression levels on the basis of staining intensity and proportion in tumor cells. The expression level of COX-2 in meningioma cells was significantly correlated with WHO grade ( P = 0.0153). In addition, COX-2 expression was significantly correlated with MIB-1 labeling index for all 76 cases of meningioma (P = 0.0075), suggesting tumor promotion by COX-2 in meningioma progression. Our results may indicate the therapeutic value of non-steroidal anti-inflammatory drugs against meningioma, especially for patients with elevated proliferation, to regulate the tumorigenic activity of COX-2 in meningioma cells.

KW - Clinicopathological analysis

KW - Cyclooxygenase-2

KW - Immunohistochemistry

KW - Meningioma

UR - http://www.scopus.com/inward/record.url?scp=84895865293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895865293&partnerID=8YFLogxK

U2 - 10.1007/s10014-012-0127-8

DO - 10.1007/s10014-012-0127-8

M3 - Article

VL - 31

SP - 23

EP - 30

JO - Brain Tumor Pathology

JF - Brain Tumor Pathology

SN - 1433-7398

IS - 1

ER -